Solomon Moshkevich, President of Clinical Diagnostics at Natera, recently sold over 23,400 shares of the company's common stock between January 20 and 21, 2026, generating proceeds of approximately $5.5 million. The sales were made under a pre-arranged trading plan to cover tax liabilities from vested Restricted Stock Units. Natera’s shares have gained 76% over the past six months, though certain analyses show the stock may currently be overvalued. Meanwhile, the company reported strong preliminary Q4 2025 revenue growth, surpassed analyst expectations, and announced key collaborations and innovations in cancer diagnostics and prenatal genetic screening.
Key Points
- Solomon Moshkevich sold 23,498 shares in January 2026, generating approximately $5.52 million, with sales executed under a Rule 10b5-1(c) plan to cover tax obligations.
- Natera’s stock price has risen 76% over six months, currently trading near $243, though some analysis suggests the shares may be overvalued relative to Fair Value.
- Recent preliminary Q4 2025 results reflect nearly 40% revenue growth year-over-year, with rising test volumes, alongside new phases of clinical collaboration and artificial intelligence innovation in cancer diagnostics.
Solomon Moshkevich, who serves as the President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), conducted stock sales totaling 23,498 shares over two trading days, January 20 and 21, 2026. These transactions realized gross proceeds amounting to approximately $5.52 million, with share prices ranging narrowly between $234.74 and $235.00 each. Despite this insider selling, Natera’s stock price continues to prosper, currently trading at $242.91 and having appreciated 76% over the past half-year. Notably, InvestingPro’s evaluation indicates the stock may be priced above its Fair Value.
On January 20, Moshkevich sold 23,205 shares. Subsequent to this transaction, his direct ownership in Natera stands at 144,992 shares. The following day, January 21, he executed a sale of a smaller lot—293 shares—adjusting his holdings to 144,699 shares.
The rationale behind these sales relates to tax obligations arising from the recent vesting of Restricted Stock Units (RSUs). These trades were carried out pursuant to a pre-established Rule 10b5-1(c) trading plan, designed to prevent any conflict with insider trading regulations by allowing planned transactions.
Beyond insider activity, Natera reported encouraging preliminary results for the fourth quarter of 2025. The company expects revenue to have grown nearly 40% year-over-year, exceeding analysts’ forecasts. Test volume during this period also rose by approximately 17%, reflecting robust operational performance. Following these announcements, Canaccord Genuity reaffirmed its Buy rating and set a price target for Natera shares at $285.00.
In addition to strong financial performance, Natera has been progressing with significant clinical collaborations and innovations. The firm recently partnered with Exelixis to conduct a pivotal phase 3 clinical trial focused on colorectal cancer patients. Here, Natera’s Signatera test will be instrumental in identifying individuals with molecular residual disease, facilitating their enrollment.
Further, Natera unveiled a new artificial intelligence model intended to enhance the molecular residual disease (MRD) assessment in cancer patients. This advanced approach will integrate diverse data modalities such as circulating tumor DNA and digital pathology imaging to refine the accuracy of the Signatera MRD test.
Research utilizing Natera’s Signatera test also contributed to a study published in JAMA Oncology, which demonstrated that celecoxib improved survival outcomes for certain colorectal cancer patients. Looking ahead, the company plans to present data from its EXPAND trial on fetal genetic screening at the Society for Maternal-Fetal Medicine’s upcoming meeting, underscoring its commitment to advancing prenatal diagnostics.
Overall, these developments highlight Natera’s ongoing efforts to innovate in specialized diagnostic areas while managing insider compliance and capital needs effectively.
Risks
- The insider stock sales could signal tax management needs rather than active bullish sentiment, but reduced insider holdings may influence investor perceptions in the short term.
- Natera’s stock appears overvalued compared to Fair Value assessments, introducing risks for investors based on potential market corrections.
- Though preliminary, revenue growth and clinical trial outcomes remain subject to variability and execution risks that could impact future performance and valuation.